Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 1/20 | 0.65 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL166809 | 0.87 | ALDH1A1 (0.71) | TBXA2RMEP1BALDH1A1MAPTCYP2C9 | |
| SCHEMBL394859 | 0.85 | CA12 (0.53) | TBXA2RMEP1BCA12CA1CA2 | |
| SCHEMBL12207094 | 0.82 | TBXA2R (0.59) | TBXA2RMEP1BCA12CA2CA9 | |
| SCHEMBL11104856 | 0.82 | ALDH1A1 (0.77) | TBXA2RMEP1BALDH1A1MAPTLMNA | |
| SCHEMBL18151701 | 0.82 | AKR1C3 (0.52) | TBXA2RCA12CA9ALDH1A1CYP2C19 | |
| SCHEMBL11119146 | 0.80 | TBXA2R (0.77) | TBXA2RMEP1BCA12CA1CA2 | |
| SCHEMBL23787605 | 0.80 | MEP1B (0.65) | MEP1BCA12CA1CA2CA9 | |
| SCHEMBL11101980 | 0.80 | TBXA2R (0.71) | TBXA2RMEP1BCA1CA2ALDH1A1 | |
| SCHEMBL163727 | 0.80 | MEP1B (0.59) | TBXA2RMEP1BCA12CA1CA2 | |
| SCHEMBL18151859 | 0.79 | ALDH1A1 (0.74) | TBXA2RMEP1BCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077372-B1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING BV (NL) | 2019-02-06 | — | — | EP | disclosed |
| US-9738600-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2017-08-22 | — | — | US | disclosed |
| US-9738600-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2017-08-22 | — | — | US | disclosed |
| US-9738600-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2017-08-22 | — | — | US | disclosed |
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-10-20 | — | — | US | disclosed |
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-10-20 | — | — | US | disclosed |
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-10-20 | — | — | US | disclosed |
| EP-3077372-A1 | ROR GAMMA (RORY) MODULATORS | Lead Pharma Cel Models IP B.V. (NL) | 2016-10-12 | — | — | EP | disclosed |
| WO-2015082533-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2015-06-11 | — | — | WO | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| EP-1451172-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | TBXA2R 177/4885MEP1B 1965/4885CA12 4771/4885 |
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | RORC, RORA, RORB | TBXA2R 1568/4885MEP1B 871/4885CA12 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.